Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
← catalyst calendarNCT06141486 · readout in 583 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
943actual
Sites
311
Countries
Argentina, Australia, Belgium +24
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-12-27 | actual | When the study began enrolling |
| Primary completion | 2028-03-24 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-03-24 | estimated | The whole study's end, after follow-up |
| First posted | 2023-11-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Multiple Sclerosis
Interventions
- Drug: Frexalimab
- Drug: Placebo
- Drug: MRI contrast-enhancing agents
Primary outcome
what the primary-completion date above is the date OFTime to onset of composite confirmed disability progression (cCDP) confirmed over 6 months in the double-blind treatment period
measured Up to 36 months
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed